Beam Therapeutics announced updated clinical data from its BEACON Phase 1/2 trial of risto-cel, a gene-edited cell therapy for sickle cell disease, showing early and sustained improvements in patients' physical function, pain, fatigue, and well-being. The data will be presented at the American Society of Hematology Annual Meeting in December 2026 and have been selected for the official press program. Beam expects to submit a Biologics License Application for risto-cel as early as the end of 2026, aiming to offer a new treatment option for patients with this severe inherited blood disorder.
Beam Therapeutics' updated clinical data presentation provides context for readers following health innovations. For readers following the health sector, here is Pluang's market snapshot as of Nov 04, 2026 20:41 WIB: out of 150 priced US health stocks, 127 rose and 19 fell today. Oscar Health Inc (OSCR) rose 9.38% to USD 35.45 with 84% buy orders, HCA Health Inc (HCA) increased 7.16% to USD 496.00, and Medline Inc. (MDLN) gained 7.10% to USD 36.51 with 98% buy orders.
The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...
Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...
The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...
Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...
Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...
